Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2024-02-06 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the announcement of a regulatory approval event and product information, not on financial results, management changes, or detailed financial data. The document length is 4322 characters, which is relatively short and typical for a press release. There is no indication of financial statements, earnings data, or detailed report content. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report.
2024-02-06 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs about receiving an order imposing a penalty from a tax authority (Tamil Nadu GST Authority). The document includes details of the order, the nature of the penalty, and the company's response. It is a regulatory announcement about a legal/tax matter rather than a financial report or earnings release. The document length is 3416 characters, which is relatively short and consistent with a regulatory announcement. There is no financial data or detailed report content, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation document. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2024-02-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about receiving an order imposing a penalty from a tax authority, with details enclosed. The document is short (3416 characters) and serves as an announcement of a regulatory event rather than a detailed report or financial statement. It does not contain financial data or detailed analysis but is a compliance disclosure to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a generic drug application by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which governs material event disclosures by listed companies. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or detailed investor presentation. The document length is 4138 characters, relatively short, and it serves as an official disclosure of a material event rather than a report or detailed filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-02-01 English
Lupin Receives Approval from U.S. FDA for Dronedarone Tablets, USP.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which governs material event disclosures by listed companies. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4138 characters, which is relatively short and typical for a press release or regulatory announcement. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other report types. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2024-02-01 English
Lupin Digital Health introduces Digital Therapeutics Certificate for Cardiologists in India in collaboration with the American College of Cardiology.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the introduction of a Digital Therapeutics Certificate for Cardiologists in India by Lupin Digital Health in collaboration with the American College of Cardiology. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The content is promotional and informative about a new initiative and collaboration, without any financial data, management changes, voting results, or regulatory filings. It is not a financial report, earnings release, management discussion, or any other formal regulatory filing. The document is a corporate announcement of a business development or partnership, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2024-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.